08:00 , Nov 4, 2013 |  BioCentury  |  Strategy

Teva blinks

With a deeply experienced CEO known for executing large, transformational deals, Teva Pharmaceutical Industries Ltd. had the chance to do something disruptive. But after the abrupt departure of President and CEO Jeremy Levin last Wednesday,...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Aposense, University of Pittsburgh deal

The university received a license to use Aposense's EarliTest imaging technology in a NIH-funded clinical trial to treat glioblastoma multiforme (GBM). The university has the right to publish the data from the trial. EarliTest comprises...
08:00 , Nov 15, 2010 |  BC Week In Review  |  Company News

Aposense, Roche deal

Roche received a non-exclusive license to use Aposense's EarliTest technology in Roche's oncology development. Roche will use EarliTest, which comprises a ML-10 apoptosis imaging agent, to monitor tumor response by PET. Roche will fund clinical...
07:00 , Jul 5, 2010 |  BioCentury  |  Finance

3Q Financial Markets Preview: Summer scrapes bottom

Biotech indices may be mostly back to or even below where they started the year, but investors aren't in a hurry to do bottom fishing over the summer. Instead, they are hopeful biotech's bad breaks...
07:00 , Jun 21, 2010 |  BC Week In Review  |  Company News

Aposense, Teva deal

Teva plans to invest up to an additional $9 million in its September 2005 deal with Aposense to co-develop therapeutics comprised of an Aposense probe conjugated to generic cytotoxic agents to treat cancer. The lead...
07:00 , Jun 14, 2010 |  BC Week In Review  |  Financial News

Aposense completes IPO

Aposense Ltd. (Tel Aviv:APOS), Petach-Tikva, Israel   Business: Cancer, Drug delivery, Diagnostic   Date completed: 6/7/10   Type: IPO   Raised: NIS95.9 million ($24.8 million)   Shares: 3 million   Price: NIS31.50   Shares after...
07:00 , Jun 14, 2010 |  BioCentury  |  Finance

IPO watch

IPO watch Israeli molecular imaging and apoptosis play Aposense Ltd. (Tel Aviv:APOS) raised NIS95.9 million ($24.8 million) through the sale of 3 million shares at NIS31.50 in an IPO on the Tel Aviv Stock Exchange...
00:53 , Jun 8, 2010 |  BC Extra  |  Financial News

Aposense prices IPO

Aposense Ltd. (Tel Aviv:APOS) raised NIS95.9 million ($24.8 million) through the sale of 3 million shares at NIS31.50 in an IPO on the Tel Aviv Stock Exchange and concurrent private placements. The price values the...
07:00 , Sep 28, 2009 |  BC Week In Review  |  Company News

Aposense, Ion Beam Applications deal

The companies expanded a 2008 deal, giving Ion exclusive, worldwide rights to co-develop and co-commercialize the radiolabeled formulation of Aposense's [18F]-ML-10. The companies will jointly fund Phase III trials of the radiolabeled formulation of malonic...
07:00 , Jun 29, 2009 |  BC Week In Review  |  Clinical News

[18F]-ML-10: Phase II data

Data from 7 patients in a Phase II trial showed a specific uptake of [18F]-ML-10 in apoptotic regions of all 8 evaluable lesions as seen with PET imaging. Following radiation treatment, increased uptake of [18F]-ML-10...